FN2 Earnings Intelligence

Exelixis, Inc. earnings overview

Latest Exelixis, Inc. (EXEL) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportExelixis, Inc. reports Tuesday, Nov 3, 2026 · After market closeConsensus EPS $0.88 · consensus revenue $647.0M
EXEL FY2026 Q3 · Calendar Q4 2026

Exelixis, Inc.

The quarter supports a constructive but conditional view: cabozantinib growth and market-share gains provide an operating base, while zanzalintinib offers the principal expansion opportunity. The thesis still depends on regulatory progress, clinical results, and execution across the pipeline.

EPS surprise+6.0%
Market move+4.8%

Get the EXEL recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.